Doxorubicin, Etoposide and Cisplatin as first-line Treatment in Advanced Adrenocortical Carcinoma


Introduction: Adrenocortical carcinoma (ACC) is a rare cancer with poor prognosis in advanced setting due to its low chemosensibility. Mitotane and cisplatin-based regimens are the most frequently used treatments.

Aim(s): We reported the efficacy and toxicity of Mitotano plus EDP schedule as first-line therapy in patients with advanced ACC.

Materials and methods: During 2009 and after surgery of the primary tumor, six patients with advanced ACC were treated with DEP schedule (Doxorubicin 40mg/m2 day 1, Etoposide 100mg/m2 days 2, 3 and 4, and Cisplatin 40mg/m2 days 3 and 4) every four weeks and Mitotane 3g/day in our Medical Oncology Department. Median age was 53 (limits: 37-61), ECOG was 0-1 and 66% were women.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: J Fonseca F, Vieitez J, Crespo G, Frunza M, Izquierdo M,

Keywords: adrenocortical carcinoma, chemotherapy, cisplatin-regimen, Doxorrubicin, Etoposide, Mitotane,

To read the full abstract, please log into your ENETS Member account.